A phase 2a, open-label study of visilizumab for treatment of perianal fistulas in patients with Crohn's disease.

Trial Profile

A phase 2a, open-label study of visilizumab for treatment of perianal fistulas in patients with Crohn's disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2012

At a glance

  • Drugs Visilizumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 06 Mar 2012 Actual end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 29 Jul 2011 Additional trial identifier 65243779 and trial centres identified and planned patient number is 20 as reported by ISRCTN: Current Controlled Trials record.
    • 27 Jul 2011 New source identified (ISRCTN: Current Controlled Trials record)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top